Scinai Immunotherapeutics (SCNI) Net Equity Issued and Repurchased (2021 - 2023)

Scinai Immunotherapeutics (SCNI) reported Net Equity Issued and Repurchased of -$947000.0 for Q4 2023, down 111.02% sequentially from $8.6 million in Q4 2021.

Scinai Immunotherapeutics (SCNI) Net Equity Issued and Repurchased (2021 - 2023) Analysis & Trends

Scinai Immunotherapeutics (SCNI) has 2 years of Net Equity Issued and Repurchased data on file, last reported at -$947000.0 in Q4 2023.

  • For the quarter ending Q4 2023, Net Equity Issued and Repurchased changed N/A year-over-year to -$947000.0; the trailing twelve-month figure through Dec 2023 stood at $36.5 million (changed N/A YoY), and the FY2024 full-year result was $2.0 million, up 1338.85% from the prior year.
  • Net Equity Issued and Repurchased fell to -$947000.0 in Q4 2023, from $8.6 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $29.5 million in Q2 2021 to a low of -$947000.0 in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Scinai Immunotherapeutics 352,860.00 -3.11 Bn -1.12 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 -947,000.00
Dec 31, 2023 -947,000.00
Dec 31, 2021 8.59 Mn
Dec 31, 2021 8.59 Mn
Sep 30, 2021 -681,000.00
Sep 30, 2021 -681,000.00
Jun 30, 2021 29.49 Mn
Jun 30, 2021 29.49 Mn
Mar 31, 2021 12.64 Mn
Mar 31, 2021 12.64 Mn